Oncology Tweetorial 

Tweetorial video: Navigating ER+ metastatic breast cancer

Explore a patient case from testing, diagnosis and treatment

Dr Paolo Tarantino

Dr Paolo Tarantino
Publication Date

Nov 2023

info Summary and next episodes

In this on-demand Tweetorial video from BREAST CANCER CONNECT, Dr Paolo Tarantino presents a patient with ER+/HER2-  de novo metastatic breast cancer, exploring the entire diagnostic and treatment process.

Clinical Takeaways

 

  • Guidelines recommend performing molecular testing with ctDNA to tailor treatment strategies in cases of recurrence or progression on endocrine therapy
  • Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2-  metastatic breast cancer harbouring an ESR1 mutation
  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Paolo Tarantino is a leading researcher in the field of breast cancer and drug development. He’s currently pursuing an advanced research fellowship at Dana Farber Cancer Institute and at Harvard Medical School (Boston, MA) and a PhD in clinical research at the University of Milan. His research focuses on the study of the HER2 oncoprotein, the biology of HER2-low breast tumors and the development of novel antibody-drug conjugates.

Dr Paolo Tarantino has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Tarantino decleares advisory role, speakers fees and/or research support from: AstraZeneca, Daiichi Sankyo, Lilly and Gilead.
Programme summary
  • clock Duration 9 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
GRASP
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
MET crusaders ESDO Global Liver Institute
DiCE
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education
COR2ED GI NURSES CONNECT PRECISION ONCOLOGY CONNECT GU NURSES CONNECT GI CONNECT
podcast Video podcast
Oncology 
Metastatic TNBC cannot wait

Optimising 1st line TROP2 ADC decisions in metastatic triple-negative breast cancer

Experts
Prof. Giuseppe Curigliano, Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca.
Explore all programmes